Citations

Showing 10 of 107964 citations.

Importance of Continuous Pulse Oximetry of the Ipsilateral Thumb/Index Finger during Transradial Angiography
Puffer, Ross C. , Kallmes, David F.

Mayo Clinic

Case Reports in Anesthesiology | December 14, 2011 | Volume: 2011 | Issue: No issue available | Pages: 1-3

10.1155/2011/653625 | PMID 22606390 Get It

We present a case of a 63-year-old male undergoing attempted basilar artery embolization using a right transradial artery approach in which continuous pulse oximetry of the ipsilateral thumb uncovered unanticipated hand ischemia during the procedure. A preprocedural evaluation using pulse oximetry of the right thumb demonstrated normal waveform and maintenance of normal oxygen saturation during manual compression of the right radial artery. This normal waveform and oxygen saturation was maintained after insertion of a 6Fr sheath into the radial artery. After insertion of a 6Fr guiding catheter into the right vertebral artery, near-complete dampening of the pulse oximetry waveform and precipitous decline in oxygen saturation were noted. Examination of the right hand demonstrated poor tissue perfusion. Immediate removal of the guiding catheter led to return of a normal waveform, oxygen saturation, and tissue perfusion. This case demonstrates the importance of continuous, intraprocedural monitoring of oxygenation of the ipsilateral hand during transradial angiography in order to avoid unanticipated perfusion abnormalities.
Let's (Not) Do It Again: Secondary Prevention of Cardiovascular Disease in Women
Hayes, Sharonne N. , Mayer, Anita P. , Files, Julia A. , Hayes, Sharonne N

Mayo Clinic

Journal of Women's Health | December 13, 2011 | Volume: 21 | Issue: 1 | Pages: 108-109

10.1089/jwh.2011.3341 | PMID 22150248 Get It

Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841
Franko, Jan , Shi, Qian , Goldman, Charles D., Pockaj, Barbara A. , Nelson, Garth D. , Goldberg, Richard M. , Pitot, Henry C., Sargent, Daniel J. , Grothey, Axel , Alberts, Steven R. , Sargent, Daniel J , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | December 13, 2011 | Volume: 30 | Issue: 3 | Pages: 263-267

10.1200/jco.2011.37.1039 | PMID 22162570 Get It

Purpose Symptoms and complications of metastatic colorectal cancer (mCRC) differ by metastatic sites. There is a paucity of prospective survival data for patients with peritoneal carcinomatosis colorectal cancer (pcCRC). We characterized outcomes of patients with pcCRC enrolled onto two prospective randomized trials of chemotherapy and contrasted that with other manifestations of mCRC (non-pcCRC). Methods A total of 2,095 patients enrolled onto two prospective randomized trials were evaluated for overall survival (OS) and progression-free survival (PFS). A Cox proportional hazard model was used to assess the adjusted associations. Results The characteristics of the pcCRC group (n = 364) were similar to those of the non-pcCRC patients in median age (63 v 61 years, P = .23), sex (57% males v 61%, P = .23), and performance status (Eastern Cooperative Oncology Group performance status 0 or 1 94% v 96%, P = .06), but differed in frequency of liver (63% v 82%, P < .001) and lung metastases (27% v 34%, P = .01). Median OS (12.7 v 17.6 months, hazard ratio [HR] = 1.3; 95% CI, 1.2 to 1.5; P < .001) and PFS (5.8 v 7.2 months, HR = 1.2; 95% CI, 1.1 to 1.3; P = .001) were shorter for pcCRC versus non-pcCRC. The unfavorable prognostic influence of pcCRC remained after adjusting for age, PS, liver metastases, and other factors (OS: HR = 1.3, P < .001; PFS: HR = 1.1, P = .02). Infusional fluorouracil, leucovorin, and oxaliplatin was superior to irinotecan, leucovorin, and fluorouracil as a first-line treatment among pcCRC (HR for OS = 0.62, P = .005) and non-pcCRC patients (HR = 0.66, P < .001). Conclusion pcCRC is associated with a significantly shorter OS and PFS as compared with other manifestations of mCRC. Future trials for mCRC should consider stratifying on the basis of pcCRC status.
Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease
Lin, Yi , Hogan, William J. , Lin, Yi

Mayo Clinic

Advances in Hematology | December 10, 2011 | Volume: 2011 | Issue: No issue available | Pages: 1-17

10.1155/2011/427863 | PMID 22190941 Get It

Mesenchymal stem cells (MSCs) represent a heterogeneous population of stromal cells with pluripotent mesenchymal differentiation potential. They have been found to have immunosuppressive properties and the ability to modulate angiogenesis and endogenous tissue repair byin vitroand animal studies. Clinical trials have examined the utility of these cells in autoimmune and inflammatory conditions. In particular, in allogeneic hematopoietic stem cell transplant (HSCT), multiple studies have been conducted to explore the use of MSC to treat acute and chronic graft-versus-host disease (GVHD) and for cotransplantation with HSCT to promote HSC engraftment and prevent GVHD. We review here the results of these studies and discuss some challenges of this treatment modality in this disease setting.
Bayesian adjustedR2for the meta‐analytic evaluation of surrogate time‐to‐event endpoints in clinical trials
Renfro, Lindsay A. , Shi, Qian , Sargent, Daniel J. , Carlin, Bradley P. , Sargent, Daniel J , Shi, Qian

Mayo Clinic

Statistics in Medicine | December 9, 2011 | Volume: 31 | Issue: 8 | Pages: 743-761

10.1002/sim.4416 | PMID 22161275 Get It

A two‐stage model for evaluating both trial‐level and patient‐level surrogacy of correlated time‐to‐event endpoints has been introduced, using patient‐level data when multiple clinical trials are available. However, the associated maximum likelihood approach often suffers from numerical problems when different baseline hazards among trials and imperfect estimation of treatment effects are assumed. To address this issue, we propose performing the second‐stage, trial‐level evaluation of potential surrogates within a Bayesian framework, where we may naturally borrow information across trials while maintaining these realistic assumptions. Posterior distributions on surrogacy measures of interest may then be used to compare measures or make decisions regarding the candidacy of a specific endpoint. We perform a simulation study to investigate differences in estimation performance between traditional maximum likelihood and new Bayesian representations of common meta‐analytic surrogacy measures, while assessing sensitivity to data characteristics such as number of trials, trial size, and amount of censoring. Furthermore, we present both frequentist and Bayesian trial‐level surrogacy evaluations of time to recurrence for overall survival in two meta‐analyses of adjuvant therapy trials in colon cancer. With these results, we recommend Bayesian evaluation as an attractive and numerically stable alternative in the multitrial assessment of potential surrogate endpoints. Copyright © 2011 John Wiley & Sons, Ltd.
The Hartford Impact on the Care of Older Adults in Transition
Holland, Diane E. , Popejoy, Lori

Mayo Clinic

Journal of Gerontological Nursing | December 9, 2011 | Volume: 37 | Issue: 12 | Pages: 12-13

10.3928/00989134-20111104-03 | PMID 22148845 Get It

Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy
Kleber, Martina , Udi, Josefina , Metzke, Barbara, Terpos, Evangelos , Roodmann, G. David, Morgan, Gareth J. , Dispenzieri, Angela , Engelhardt, Monika , Einsele, Hermann , Wäsch, Ralph , Dispenzieri, Angela , Terpos, Evangelos , Morgan, Gareth J

Mayo Clinic

Leukemia & Lymphoma | December 9, 2011 | Volume: 53 | Issue: 6 | Pages: 1057-1061

10.3109/10428194.2011.644548 | PMID 22149167 Get It

INTEGRATING VA'S NDF-RT DRUG TERMINOLOGY WITH PHARMGKB: PRELIMINARY RESULTS
Pathak, Jyotishman , WEISS, LAURA C., Durski, Matthew J., Zhu, Qian , Freimuth, Robert R. , Chute, Christopher G.

Mayo Clinic

Biocomputing 2012 | December 9, 2011 | Volume: No volume available | Issue: No issue available | Pages: 400-409

10.1142/9789814366496_0039 Get It

Does Helicopter Emergency Medical Service Transfer Offer Benefit to Patients With Stroke?
Olson, Michael D. , Rabinstein, Alejandro A.

Mayo Clinic

Stroke | December 9, 2011 | Volume: 43 | Issue: 3 | Pages: 878-880

10.1161/strokeaha.111.640987 | PMID 22156702 Get It

Background and Purpose— Helicopter transportation of patients with acute stroke who have received recombinant tissue-type plasminogen activator is commonly considered the best option. We evaluated if transportation by helicopter can reduce complications and improve clinical outcomes in patients with acute stroke. Methods— We conducted a review of consecutive patients with acute ischemic stroke transferred to our hospital after intravenous thrombolysis initiated at a referral center. Results— A total of 122 patient transportations were analyzed, 94 by air and 28 by ground. Time from activation of the transport system to arrival at our hospital was significantly shorter with air transportation (53 versus 68 minutes, P =0.04). Two complications were noted in the air group and no complications were noted in the ground group ( P =1.0). All other outcome measures were not significantly different between groups. Conclusions— Air transfer of patients with acute ischemic stroke treated with thrombolysis does not seem to impart any benefit to patient outcomes when compared with ground transport. Therefore, ground transport should be considered for these patients unless they are being considered for emergency endovascular rescue therapy.
Innovation in myeloma treatments PARP excellence!
Fonseca, Rafaël , Fonseca, Rafael

Mayo Clinic

Blood | December 8, 2011 | Volume: 118 | Issue: 24 | Pages: 6234-6235

10.1182/blood-2011-10-381129 | PMID 22161848 Get It